Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

导出 LinkOut

翻译打印收藏纠错

作者： Ling,Liu ^[1] ; Jirong,Lu ^[1] ; Barrett W,Allan ^[2] ; Ying,Tang ^[2] ; Jonathan,Tetreault ^[1] ; Chi-Kin,Chow ^[1] ; Barbra,Barmettler ^[2] ; James,Nelson ^[2] ; Holly,Bina ^[1] ; Lihua,Huang ^[3] ; Victor J,Wroblewski ^[4] ; Kristine,Kikly ^[1]

作者单位： Biotechnology Discovery Research, Indianapolis, IN, USA. ^[1] Applied Molecular Evolution, Lilly Biotechnology Center, San Diego, CA, USA. ^[2] Bioproduct Research and Development, Indianapolis, IN, USA. ^[3] Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. ^[4]

关键词 IL-17A monoclonal antibody anti-IL-17A ixekizumab

DOI 10.2147/JIR.S100940

PMID 27143947

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览32

Journal of inflammation research

2016年9卷

39-50页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

Journal of inflammation research

相似文献

Journal of inflammation research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

Journal of inflammation research

相似文献

Journal of inflammation research

相关期刊

检索历史清除